Anticancer

Carnosol
Catalog No: CFN99956

Carnosol, a novel agonist of TRPA1 with an EC50 value of 12.46 uM, which exhibits anti-inflammatory, anti-nociceptive, hepatoprotective, antioxidant, anticarcinogen, anti-angiogenic, anti- invasive and antimetastatic properties. Carnosol can cause a significant decrease in both bacterial and yeast growth whilst, it may prove useful as a food antioxidant which could also contribute to the retardation of the microbial spoilage of foods; it also can inhibit adipocyte differentiation in mouse 3T3-L1 cells through induction of phase2 enzymes and activation of glutathione metabolism, it may be a potential drug against obesity-related diseases.
(-)-Maackiain
Catalog No: CFN98030

(-)-Maackiain, a phytoalexin, which is an anti-allergic compound that suppresses the up-regulation of the histamine H1 receptor (H1R) gene. It shows significant growth inhibitory action on the growth of the human lymphoblastoid cell lines Molt and Raji, and shows a strong larvicidal effect against 4th instar larvae of Aedes aegypti(LC50=21.95±1.34ug/mL).
Parthenolide
Catalog No: CFN98034

Parthenolide exhibits anti-cancer, anti-inflammatory, immunomodulatory, anti-Leishmania, and antimigraine effects, it inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.Parthenolide is also an inhibitor of the nuclear factor-kappaB pathway, can ameliorate cardiovascular derangement and outcome in endotoxic shock in rodents.
Ergosterol peroxide
Catalog No: CFN98035

Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Foxo3a activity by inhibiting pAKT and c-Myc and activating pro-apoptotic protein Puma and Bax to induce cancer cell death.Ergosterol peroxide can ameliorate TGF-β1-induced activation of kidney fibroblasts, it has the potential to be developed as a therapeutic agent to prevent renal fibrosis.
Lovastatin
Catalog No: CFN99961

Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM in a cell-free assay, has a direct cellular effect independent of a cholesterol-lowering effect and delays the onset and progression of diabetic nephropathy. It has a potential application to treat PD via antioxidant effect, and it promotes fibrosis and epithelial to mesenchymal transition, by regulating the production of CCN2 in human gingival fibroblasts.